Reducer Overview
CCS Angina Scores

Reducer for the treatment of refractory angina

Neovasc Reducer   The Neovasc Reducer is a percutaneous treatment for refractory angina. Refractory angina results from inadequate blood flow to the heart muscle that cannot be managed through conventional drug, catheter or surgical therapy. The disease causes constant and severe heart pain and significant disability that negatively impacts the quality of life for millions of patients. The global incidence of refractory angina is growing.

The Reducer procedure is similar to a coronary stent implantation and takes approximately 20 minutes using standard catheter-based techniques.

A first-in-man study of the Reducer in 15 patients followed for three years has demonstrated excellent safety and efficacy in terms of reducing angina pain and other objective improvements in myocardial function. Neovasc is presently enrolling patients in the COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) study. COSIRA is a double-blind, randomized, sham-controlled, multicenter, prospective trial intended to further demonstrate the safety and efficacy of the Reducer procedure.

 

CCS Angina Scores

Class I

Angina with strenuous, rapid, or prolonged exertion (Ordinary physical activity such as climbing stairs does not provoke angina.)

Class II

Slight limitation of ordinary activity (Angina occurs with postprandial, uphill, or rapid walking; when walking more than two blocks of level ground or climbing more than one flight of stairs; during emotional stress; or in the early hours after awakening.)

Class III

Symptoms with everyday living activities, i.e. moderate limitation. Marked limitation of ordinary activity (Angina occurs with walking 1-2 blocks or climbing a flight of stairs at a normal pace.)

Class IV

Inability to perform any activity without angina or angina at rest, i.e. severe limitation.

 

The Neovasc Reducer is protected by issued US/International patents and related applications.

The Reducer is currently an investigational device and is not available for sale.

Read JACC Study